医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terns Pharmaceuticals Appoints Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer

2019年07月01日 PM06:00
このエントリーをはてなブックマークに追加


 

FOSTER CITY, Calif. & SHANGHAI

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis (NASH) and cancer, announced today the appointment of Ankang Li, Ph.D., J.D., CFA as Chief Financial Officer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190701005203/en/

Ankang Li, Chief Financial Officer (Photo: Business Wire)

Ankang Li, Chief Financial Officer (Photo: Business Wire)

“Dr. Li joins Terns with over 10 years of experience in investment banking, business development, legal advisory, and biomedical research,” said Weidong Zhong, Ph.D., President and CEO of Terns. “We are pleased to welcome Dr. Li to Terns. He has a strong record of driving growth in the biopharma industry.”

At Terns, Dr. Li will be responsible for corporate financing, financial reporting, accounting, risk management, business development, and investor relations.

Prior to joining Terns, Dr. Li was the Executive Director of Healthcare Investment Banking at Goldman Sachs, where he was responsible for Asia ex-Japan investment banking and led many high-profile IPOs for biotechnology and other healthcare clients. Before that, Dr. Li was a Director at the Asia Pacific Innovation Hub at Merck (known as MSD outside the U.S. and Canada), overseeing business development and licensing transactions in the region. Dr. Li also worked at both Davis Polk and Ropes & Gray, advising clients on capital markets and M&A transactions. Early in his career, he conducted biomedical research at the Salk Institute.

Ankang Li received a Juris Doctor degree from The University of Chicago Law School, a Ph.D. in Biomedical Sciences from Baylor College of Medicine, a Master of Science degree in Biological Sciences from the National University of Singapore, and a Bachelor of Science degree in Biochemistry from Fudan University. He is a CFA charter holder.

“Terns has emerged as one of the leading biopharmaceutical companies developing therapeutics for liver disease,” commented Dr. Li. “I look forward to working with Terns’ board and the leadership team to help advance their innovative pipeline and programs to benefit patients in China and worldwide.”

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients in China and other global markets.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190701005203/en/

CONTACT

US Media Contact:

Margaret Robinson

+1 (415) 690 0084

China Media Contact:

Yan Wan

+86 186 1196 5371

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生